Formycon AG Sustainability Profile
Formycon AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its expertise in the development of biosimilars. Founded in 2002, the company has established a strong presence in Europe and beyond, focusing on innovative therapies that enhance patient care. With a commitment to quality and efficacy, Formycon AG offers a range of biosimilar products that stand out for their rigorous development processes and regulatory compliance. The company has achieved significant milestones, including successful partnerships and product launches that underscore its position in the competitive biopharmaceutical landscape. Recognised for its scientific excellence, Formycon AG continues to drive advancements in the industry, making substantial contributions to the accessibility of biologic treatments for patients worldwide.
DitchCarbon Score
How does Formycon AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Formycon AG's score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Formycon AG's reported carbon emissions
Formycon AG, headquartered in Germany, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. As of now, Formycon AG does not inherit emissions data from any parent or related organizations, meaning all information is self-reported and reflects their independent status in terms of climate commitments. In the context of the biopharmaceutical industry, companies are increasingly focusing on sustainability and carbon neutrality. While Formycon AG has not yet established specific targets or initiatives, the industry trend suggests a growing emphasis on reducing carbon footprints and enhancing environmental responsibility. Overall, without specific emissions data or reduction commitments, Formycon AG's current climate strategy remains unclear, but the company is positioned within an industry that is progressively prioritising climate action.
How Carbon Intensive is Formycon AG's Industry?
How Carbon Intensive is Formycon AG's Location?
Formycon AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Formycon AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
